

Product datasheet for TL200518V

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

AATK Human shRNA Lentiviral Particle (Locus ID 9625)

Product data:

Product Type: shRNA Lentiviral Particles

Product Name: AATK Human shRNA Lentiviral Particle (Locus ID 9625)

Locus ID: 9625

Synonyms: AATYK; AATYK1; LMR1; LMTK1; p35BP; PPP1R77

Vector: pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: AATK - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble

control), 0.5 ml each, >10^7 TU/ml.

RefSeq: NM 001080395, NM 004920, NM 001080395.1, NM 001080395.2, NM 004920.1,

NM 004920.2, BC047378

UniProt ID: Q6ZMQ8

Summary: The protein encoded by this gene contains a tyrosine kinase domain at the N-terminus and a

proline-rich domain at the C-terminus. This gene is induced during apoptosis, and expression

of this gene may be a necessary pre-requisite for the induction of growth arrest and/or apoptosis of myeloid precursor cells. This gene has been shown to produce neuronal differentiation in a neuroblastoma cell line. Two transcript variants encoding different

isoforms have been found for this gene. [provided by RefSeq, Jun 2011]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>.

If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.





Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).